Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 9/20 | 0.66 |
| ▸ | AR | P10275 | 5/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 3/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15059136 | 0.87 | VDR (0.87) | VDRARESR1ESR2HDAC3 | |
| SCHEMBL13203811 | 0.86 | VDR (0.60) | VDRARCYP2C19RXRARXRB | |
| SCHEMBL13221244 | 0.84 | VDR (0.58) | VDRARCYP2C19RXRARXRB | |
| SCHEMBL2942518 | 0.84 | VDR (0.58) | VDRARCYP2C19 | |
| SCHEMBL13203626 | 0.83 | VDR (0.60) | VDRARCYP2C19HDAC3HDAC6 | |
| SCHEMBL29754251 | 0.83 | CYP2C19 (0.62) | VDRARCYP2C19RXRARXRB | |
| SCHEMBL13945999 | 0.83 | CYP2C19 (0.62) | VDRARCYP2C19RXRARXRB | |
| SCHEMBL2951763 | 0.82 | VDR (0.56) | VDRARCYP2C19RXRARXRB | |
| SCHEMBL2965658 | 0.82 | VDR (0.65) | VDRARCYP2C19HDAC3HDAC6 | |
| SCHEMBL2944976 | 0.82 | VDR (0.68) | VDRARCYP2C19HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772425-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772425-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772425-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7750184-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750184-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750184-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090227604-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-20090227604-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-20090227604-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-7566803-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-07-28 | — | — | US | disclosed |
| CN-100408539-C | Vitamin d receptor modulators | LILLY CO ELI (US) | 2008-08-06 | — | — | CN | disclosed |
| US-20060293385-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY, AN INDIANA CORPORATION | 2006-12-28 | — | — | US | disclosed |
| EP-1687265-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20060094778-A1 | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators | ELI LILLY AND COMPANY, AN INDIANA CORPORATION | 2006-05-04 | — | — | US | disclosed |
| CN-1714070-A | Vitamin d receptor modulators | LILLY CO ELI (US) | 2005-12-28 | — | — | CN | disclosed |
| EP-1587906-A2 | VESICANT TREATMENT WITH PHENYL-PHENYL TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1565422-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005051898-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004063345-A2 | VESICANT TREATMENT WITH PHENYL-PHENYL TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004048309-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227604-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP24A1, CYP2R1 | VDR 1/4885AR 719/4885CYP2C19 803/4885 |
| US-20060293385-A1 | Vitamin d receptor modulators | VDR, CYP24A1, CYP2R1 | VDR 1/4885AR 535/4885CYP2C19 1075/4885 |
| US-20060094778-A1 | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | VDR 1/4885AR 177/4885CYP2C19 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.